Best Agrolife FY26 Revenue Down 31% to ₹1,257 Cr, PAT Plunges to ₹9 Cr

AGRICULTURE
Whalesbook Corporate News Logo
AuthorIshaan Verma|Published at:
Best Agrolife FY26 Revenue Down 31% to ₹1,257 Cr, PAT Plunges to ₹9 Cr
Overview

Best Agrolife reported a 31% revenue drop to ₹1,257 crore for FY26 and a significant profit decline to ₹9 crore. The company cited conscious sales calibration and market conditions for the weaker performance, especially in Q4.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

Best Agrolife Reports Steep Decline in FY26 Revenue and Profit

Best Agrolife Ltd reported ₹1,257 crore in revenue for FY26 and a net profit after tax (PAT) of ₹9 crore.

Reader Takeaway: Revenue down 31%, PAT hit by strategic sales cuts and market headwinds.

What just happened

Best Agrolife Limited announced its financial results for the quarter and financial year ended March 31, 2026. The company's revenue for the full fiscal year (FY26) stood at ₹1,257 crore, a significant 31% decrease compared to ₹1,814 crore in FY25. Net profit after tax (PAT) for FY26 plummeted to ₹9 crore, down from ₹70 crore in the previous year.

The fourth quarter (Q4 FY26) also showed weakness, with revenue falling 43% year-on-year to ₹156 crore from ₹274 crore in Q4 FY25. The company reported a net loss of ₹37 crore for Q4 FY26, compared to a loss of ₹22 crore in the same period last year. EBITDA for Q4 FY26 was negative at ₹-27 crore.

Why this matters

The sharp decline in revenue and profitability signals significant challenges for Best Agrolife. The company's strategic decision to calibrate sales in March, avoiding low-realization deals, impacted revenue by an estimated ₹50-70 crore in the fourth quarter. This focus on medium-term profitability over short-term sales has led to weak quarterly results.

The backstory

Best Agrolife has been working on improving its working capital. Inventory levels have been reduced from ₹958 crore in FY24 to ₹773 crore in FY25 and further to ₹651 crore by March 31, 2026. This indicates a focus on operational efficiency.

What changes now

Management is looking to expand its crop protection portfolio by focusing on biostimulants and new patented products like Fluzam and Midcotin. They are also weeding out non-performing dealers to improve distribution channels. The company aims to leverage its intellectual property and technical manufacturing capabilities.

Risks to watch

Investors have raised concerns about high receivables, which stood at approximately ₹500 crore. The company's business remains dependent on monsoons and subject to raw material price volatility. Historical misses in guidance also remain a point of concern for investors.

Peer comparison

While the filing does not provide direct peer comparison data, management acknowledged the company's 'startup-like' status in its branded business, which is 3-4 years old, in response to performance versus peers and missed guidance.

Context metrics (time-bound)

  • FY26 Revenue: ₹1,257 crore (vs ₹1,814 crore in FY25)
  • FY26 PAT: ₹9 crore (vs ₹70 crore in FY25)
  • Q4 FY26 Revenue: ₹156 crore (vs ₹274 crore in Q4 FY25)
  • Q4 FY26 PAT: ₹-37 crore (vs ₹-22 crore in Q4 FY25)
  • Inventory as of March 31, 2026: ₹651 crore (down from ₹773 crore in FY25)

What to track next

Investors will be closely watching Best Agrolife's ability to manage its receivables cycle effectively and generate cash from its inventory. The successful launch and scaling of its new patented products in FY27 will be crucial for driving future profitability. Monitoring guidance adherence will also be key.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.